Patents by Inventor Hanswalter Zentgraf

Hanswalter Zentgraf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9297812
    Abstract: The present invention relates to the field of diagnostic tests and diagnostic tools. Specifically, contemplated is to a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer comprising contacting the sample with an antibody which specifically binds to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide under conditions which allow for binding of said antibody to the epitope and determining binding of the antibody to the epitope, whereby cancer is diagnosed. Further contemplated are antibodies which specifically bind to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide and a device or kit comprising such antibodies.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: March 29, 2016
    Assignees: Deutsches Krebsforschungzentrum, Ruprecht-Karl-Universit├Ąt Heidelberg
    Inventors: Hanswalter Zentgraf, Ulrike Zentgraf, Andreas Von Deimling, David Capper
  • Patent number: 8367347
    Abstract: The present invention relates to methods for the diagnosis of a brain tumor and for the estimation of a prognosis for patients having a brain tumor using the presence/absence of a particular IDH1 mutation as a marker.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: February 5, 2013
    Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts and Ruprecht-Karls-Univeristat Heidelberg
    Inventors: Christian Hartmann, Andreas von Deimling, Hanswalter Zentgraf, David Capper, Guido Reifenberger, Michael Weller, Wolfgang Wick
  • Publication number: 20100291590
    Abstract: The present invention relates to methods for the diagnosis of a brain tumor and for the estimation of a prognosis for patients having a brain tumor using the presence/absence of a particular IDH1 mutation as a marker.
    Type: Application
    Filed: December 14, 2009
    Publication date: November 18, 2010
    Inventors: Christian Hartmann, Andreas von Deimling, Hanswalter Zentgraf, David Capper, Guido Reifenberger, Michael Weller, Wolfgang Wick
  • Patent number: 7713712
    Abstract: The present invention relates to an antibody active against a fusion polypeptide comprising a histidine portion, a process for the preparation thereof and its use.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: May 11, 2010
    Assignee: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
    Inventors: Hanswalter Zentgraf, Claudia Tessmer, Iris Velhagen, Susanne Schwinn, Manfred Frey
  • Publication number: 20090221040
    Abstract: The present invention relates to an antibody active against a fusion polypeptide comprising a histidine portion, a process for the preparation thereof and its use.
    Type: Application
    Filed: May 14, 2009
    Publication date: September 3, 2009
    Applicant: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Hanswalter ZENTGRAF, Claudia TESSMER, Iris VELHAGEN, Susanne SCHWINN, Manfred FREY
  • Patent number: 7029866
    Abstract: The invention is directed to a method of diagnosis of the existence and/or the pathological developmental stage and/or the grade of malignancy of carcinomas and/or sarcomas in mammals characterized by the preparation of a body sample of said mammals and the determination of the overexpression of the protein Nup88 in said sample and to antibodies suitable for performing the same.
    Type: Grant
    Filed: October 10, 2000
    Date of Patent: April 18, 2006
    Inventors: Hanswalter Zentgraf, Susanne Franz, Angel Alonso, Nerea Martinez
  • Patent number: 6790940
    Abstract: The present invention relates to an antibody active against a fusion polypeptide comprising a histidine portion, a process for the preparation thereof and its use.
    Type: Grant
    Filed: February 9, 1998
    Date of Patent: September 14, 2004
    Assignee: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Hanswalter Zentgraf, Claudia Tessmer, Iris Velhagen, Susanne Schwinn, Manfred Frey
  • Publication number: 20040105854
    Abstract: The present invention relates to an antibody active against a fusion polypeptide comprising a histidine portion, a process for the preparation thereof and its use.
    Type: Application
    Filed: October 14, 2003
    Publication date: June 3, 2004
    Applicant: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Hanswalter Zentgraf, Claudia Tessmer, Iris Velhagen, Susanne Schwinn, Manfred Frey
  • Patent number: 6214541
    Abstract: The present invention relates to a method of detecting specific antibodies directed against HPV proteins in body fluids, comprising the following steps: (I) incubating a native carrier material-bound HPV protein with body fluids, and (II) reacting specific antibodies (a) bound to the HPV protein with labeled antibodies (b) directed against antibodies (a) or with unlabeled antibodies (b) and the latter with labeled antibodies (c) directed against antibodies (b). Furthermore, this invention concerns a kit usable for this purpose.
    Type: Grant
    Filed: March 9, 1998
    Date of Patent: April 10, 2001
    Assignee: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
    Inventors: Hanswalter Zentgraf, Manfred Frey, Iris Velhagen, Regina Martens, Wolfgang Meschede, Michael Pawlita, Joris Braspenning, Masimo Tommasino
  • Patent number: 6051384
    Abstract: The invention relates to a method of detecting p53-specific antibodies in body fluids wherein support-bound p53 and/or support-bound fragments thereof comprising binding regions for p53-specific antibodies are incubated with body fluids and the specific antibodies (a) bound to p53 and/or said fragments are allowed to reactwith labelled antibodies (b) directed against antibodies (a), orwith unlabelled antibodies (b) while the latter are allowed to react with labelled antibodies (c) directed against antibodies (b), with the labelling being non-radioactive in either case.The invention further relates to a kit useful therefor. Also, the invention relates to p53 fragments and DNA sequences coding for them, said fragments comprising binding regions for p53-specific antibodies, as well as to methods of preparing them.
    Type: Grant
    Filed: May 30, 1994
    Date of Patent: April 18, 2000
    Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Hanswalter Zentgraf, Peter Schranz, Martin Volkmann, Claudia Tessmer, Ralf Klein